Inhibition of the alloantibody response by CD95 ligand

被引:75
|
作者
Arai, H
Chan, SY
Bishop, DK
Nabel, GJ
机构
[1] UNIV MICHIGAN,HOWARD HUGHES MED INST,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109
[2] UNIV MICHIGAN,HOWARD HUGHES MED INST,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109
[3] UNIV MICHIGAN,DEPT SURG,SECT GEN SURG,ANN ARBOR,MI 48109
关键词
D O I
10.1038/nm0897-843
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We investigated the effect of Fas/APO1-ligand (CD95L) gene transfer on allogeneic immune responses in vivo. A colon carcinoma cell line from BALB/c mice, CT26, was stably transfected with a vector encoding mouse CD95L and was inoculated into C57BL/6 mice. CD95L expression markedly reduced allogeneic cytotoxic T lymphocyte and helper T lymphocyte activity directed toward CT26. Strikingly, expression of CD95L on these allogeneic tumors completely inhibited the generation of alloantibodies of both IgM and IgG subclasses. Thus, CD95L inhibited alloantibody production and conferred localized immune suppression through this mechanism. These results provide insight into the role of CD95L in regulating the alloantibody response and the generation of local immune responses.
引用
收藏
页码:843 / 848
页数:6
相关论文
共 50 条
  • [21] Role of apoptosis and CD95/CD95 ligand expression in chronic hepatitis C and HIV infection
    Filipowicz, E
    Ololade, O
    Xiao, SY
    Adeboyega, PA
    LABORATORY INVESTIGATION, 2001, 81 (01) : 196A - 196A
  • [22] Evaluation of CD95 (APO-1/FAS) and the CD95 ligand in acute myelogenous leukemia
    Mestice, A
    Specchia, G
    Coppi, MR
    Palumbo, G
    Carluccio, P
    Attolico, I
    Quarta, A
    Liso, V
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 74 - 74
  • [23] The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis
    Tolomeo, M
    Dusonchet, L
    Meli, M
    Grimaudo, S
    D'Alessandro, N
    Papoff, G
    Ruberti, G
    Rausa, L
    CELL DEATH AND DIFFERENTIATION, 1998, 5 (09): : 735 - 742
  • [24] Synergy of CD95 ligand and teniposide: No role of cleavable complex formation and enhanced CD95 expression
    Winter, S
    Roth, W
    Dichgans, J
    Weller, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 341 (2-3) : 323 - 328
  • [25] CD95-ligand and hyperosmolarity trigger CD95/EGF receptor association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and disc formation.
    Reinehr, R
    Schliess, F
    Häussinger, D
    HEPATOLOGY, 2003, 38 (04) : 570A - 570A
  • [26] CD95-tyrosine nitration inhibits hyperosmotic and CD95 ligand-induced CD95 activation in rat hepatocytes
    Reinehr, R
    Görg, B
    Höngen, A
    Häussinger, D
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (11) : 10364 - 10373
  • [27] Dysregulation of CD95/CD95 ligand apoptotic pathway in CD3+ large granular lymphocyte leukemia
    Lamy, T
    Liu, JH
    Landowski, TH
    Dalton, WS
    Loughran, TP
    BLOOD, 1998, 92 (12) : 4771 - 4777
  • [28] p53 differentially regulates CD95 receptor and CD95 ligand expression in hepatoma cells in response to chemotherapeutic drugs.
    Mueller, M
    Fridman, SL
    Lehlbach, K
    Volkmann, M
    Stremmel, W
    Galle, PR
    Krammer, PH
    HEPATOLOGY, 1997, 26 (04) : 510 - 510
  • [29] Lack of proapoptotic activity of soluble CD95 ligand is due to its failure to induce CD95 oligomers
    Jang, SY
    Krammer, PH
    Salgame, P
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2003, 23 (08): : 441 - 447
  • [30] Differential and mutually exclusive expression of CD95 and CD95 ligand in epithelia of normal pancreas and chronic pancreatitis
    Hasel, C
    Rau, B
    Perner, S
    Sträter, J
    Möller, P
    LABORATORY INVESTIGATION, 2001, 81 (03) : 317 - 326